Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies

This study is conducting long-term safety follow-up for patients who previously received a CAR T-cell therapy (a type of immune cell cancer treatment) made by Miltenyi Biotec in a prior clinical trial. The goal is to monitor patients for at least 15 years to check for any delayed or long-term side effects. **You may be eligible if...** - You previously received a Miltenyi CAR T-cell therapy as part of a clinical trial at least 12 months ago - You are able to provide informed consent to participate in follow-up **You may NOT be eligible if...** - There are no exclusion criteria for this long-term follow-up study Talk to your doctor to see if this trial is right for you.